What happened
One of this week's top roller-coaster stocks, biotech Impel NeuroPharma (NASDAQ: IMPL), experienced another queasy price lurch on Friday. The company's shares fell by almost 24% on the pricing of an upcoming share issue.
So what
After market hours on Thursday, Impel NeuroPharma set the price for its previously announced 3 million-share issue of common stock at $15 per share. The company is also granting the issue's underwriters a 30-day option to buy up to an additional 450,000 shares at that price. The issue should close next Tuesday, Sept. 14, the company said.
Image source: Getty Images.
That $15 is well down from Thursday's close of just over $21 per share. It's also significantly south of the $18.65 on which Impel NeuroPharma based its proceeds estimates in the previous prospectus on the sale.
Impel NeuroPharma reiterated that it aims to use said proceeds "to fund the initial and ongoing commercial launch activities and market development of Trudhesa, advance INP105 into a clinical proof-of-concept trial in patients with [autism spectrum disorder], and for working capital and general corporate purposes."
Now what
Which is why investors shouldn't necessarily be so downbeat about Impel NeuroPharma's cup-in-hand move.
Trudhesa -- a nasal spray that treats migraines -- is the company's first FDA-approved medicine. While it won't be the only product of its kind on the market, it will give the onetime clinical-stage biotech its crucial first source of revenue. It's also encouraging that the company will be channeling capital to develop INP105, which targets acute agitation in patients suffering from bipolar disorder and schizophrenia.
10 stocks we like better than Impel NeuroPharma, Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Impel NeuroPharma, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of August 9, 2021
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
